NGM Stock Forecast, Price & News (NGM Biopharmaceuticals)
NASDAQ:NGM

NGM Biopharmaceuticals Stock Forecast, Price & News

$25.43
-0.97 (-3.67 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.03
Now: $25.43
$26.85
50-Day Range
$25.67
MA: $28.56
$31.93
52-Week Range
$14.70
Now: $25.43
$32.12
Volume117,212 shs
Average Volume303,715 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
NGM Biopharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NGM
CUSIPN/A
CIKN/A
Phone650 243 5555
Employees186
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.54 million
Book Value$4.96 per share

Profitability

Net Income$-42,790,000.00

Miscellaneous

Market Cap$1.95 billion
Next Earnings Date5/12/2021 (Estimated)
OptionableOptionable

Headlines

NGM Biopharmaceuticals (NASDAQ:NGM) Shares Down 6.8%
March 26, 2021 |  americanbankingnews.com
NGM Biopharmaceuticals Inc Registered Shs Strong Buy
January 10, 2021 |  markets.businessinsider.com
NGM Bio prices $125M share offering
January 7, 2021 |  seekingalpha.com
NGM Bio Announces Proposed Offering of Common Stock
January 4, 2021 |  finance.yahoo.com
NGM Jan 2021 20.000 call
December 24, 2020 |  au.finance.yahoo.com
NGM Jan 2021 15.000 call
December 24, 2020 |  au.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

161st out of 2,011 stocks

Pharmaceutical Preparations Industry

64th out of 772 stocks

Analyst Opinion: 3.6Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$25.43
-0.97 (-3.67 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NGM Biopharmaceuticals (NASDAQ:NGM) Frequently Asked Questions

Is NGM Biopharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NGM Biopharmaceuticals stock.
View analyst ratings for NGM Biopharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than NGM Biopharmaceuticals?

Wall Street analysts have given NGM Biopharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NGM Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for NGM Biopharmaceuticals
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its quarterly earnings data on Wednesday, March, 3rd. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.07. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 29.47% and a negative net margin of 91.64%.
View NGM Biopharmaceuticals' earnings history
.

How has NGM Biopharmaceuticals' stock been impacted by Coronavirus?

NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NGM stock has increased by 65.7% and is now trading at $25.43.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NGM?

7 Wall Street analysts have issued 12 month target prices for NGM Biopharmaceuticals' shares. Their forecasts range from $30.00 to $52.00. On average, they expect NGM Biopharmaceuticals' share price to reach $39.11 in the next year. This suggests a possible upside of 53.8% from the stock's current price.
View analysts' price targets for NGM Biopharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:
  • Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 61)
  • Dr. David J. Woodhouse, CEO & Director (Age 51, Pay $615.75k)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 58, Pay $625.75k)
  • Ms. Siobhan Nolan Mangini, CFO and Principal Financial & Accounting Officer (Age 40)
  • Mr. Alexander Duke Schwartz, Exec. Director of Investor Relations
  • Ms. Valerie L. Pierce J.D., Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 58)
  • Mr. Brian Muma, VP of HR
  • Dr. Hui Tian, Sr. VP of Research
  • Dr. Alex DePaoli, Chief Translational Officer & Sr. VP
  • Dr. Wenyan Shen, Sr. VP of Biologics and CMC

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals CEO David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among NGM Biopharmaceuticals' employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NGM Biopharmaceuticals' key competitors?

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $25.43.

How much money does NGM Biopharmaceuticals make?

NGM Biopharmaceuticals has a market capitalization of $1.95 billion and generates $103.54 million in revenue each year. The company earns $-42,790,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does NGM Biopharmaceuticals have?

NGM Biopharmaceuticals employs 186 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

Where are NGM Biopharmaceuticals' headquarters?

NGM Biopharmaceuticals is headquartered at 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650 243 5555 or via email at [email protected]


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.